Santander explores sale of $8bn stake in Polish unit
The Spanish financial giant, which is shifting its focus towards growth in the Americas, has enlisted an adviser to assess the future of its 62% stake in Santander Bank Polska, Bloomberg reported citing sources.
Santander has begun reaching out to potential investors to gauge their interest in the stake, although discussions remain in their early stages, people privy to the development said.
It is still possible that the bank may choose to retain its holding or pursue a partial sale of the shares, the sources indicated.
In September, Santander raised 2.46bn zlotys ($627m) by selling a 5.2% interest in its Polish operation.
However, a full sale of the business could be challenging, as the scale of the operation may make it difficult for local financial institutions to complete a purchase.
The size of Santander Bank Polska could present a significant barrier to a domestic acquisition.
This review of the Polish unit aligns with the bank's broader strategic shift under the leadership of Santander executive chair Ana Botín.
The lender has been placing greater emphasis on expanding its footprint in the Americas, while reducing its focus on its European operations.
Recent efforts include new digital banking initiatives in the US and Mexico, along with a new banking license acquired in Canada.
Santander Bank Polska continues to be one of Poland's largest banks, serving a customer base of 7.5 million individuals. Nationale-Nederlanden OFE holds a 5% stake in the bank.
"Santander explores sale of $8bn stake in Polish unit" was originally created and published by Retail Banker International, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Europeans pile into local ETFs at record rate, at expense of US stocks
By Iain Withers LONDON (Reuters) -European investors have put more money into local stock index-trackers so far in 2025 than in any full-year on record, with demand for defence funds booming, data shows, as President Donald Trump's erratic trade policy hits their appetite for U.S. shares. Investors had ploughed a net 39.4 billion euros ($46.2 billion) into European-focused Exchange Traded Funds (ETFs) domiciled in the region by the end of July - topping every full-year tally since 2008 when Morningstar first collected the data. Invest in Gold Thor Metals Group: Best Overall Gold IRA American Hartford Gold: #1 Precious Metals Dealer in the Nation Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase The net inflows in 2025 are up more than three-fold on last year's total, helping power the region's ETF market to 2.4 trillion euros in assets, according to Morningstar. In contrast, U.S.-focused ETFs have attracted 12.5 billion euros of net new money this year, down 40% on the same period in 2024 and the lowest tally for the period in three years. The trend towards picking local stocks has been visible across the biggest investment houses. U.S. investment giant BlackRock, the largest ETF provider, France's Amundi, Deutsche Bank's DWS and Switzerland's UBS have all seen strong local inflows, the Morningstar data shows. While U.S. stocks have rebounded to record highs after an initial sell-off following Trump's 'Liberation Day' trade tariffs on April 2, net inflows into European-focused ETFs have topped U.S.-focused funds every month this year except in January, according to the data. Global equity funds have also gained ground this year, with net inflows into European-domiciled products up 40% to 47.3 billion euros, while UK-focused ETFs have continued to struggle, suffering 1.2 billion euros of net outflows after a small inflow last year. Investors in the region have also backed defence-themed ETFs in huge numbers, as European countries race to rebuild their militaries. Europe-based security ETFs have pulled in 7.6 billion euros of net inflows so far this year, Morningstar said, more than three times the next biggest ETF category, artificial intelligence. Monika Calay, an analyst at Morningstar, said that unpredictable trade policy under President Trump had cooled European investors' appetite for U.S. funds, but added that they remained a big part of most portfolios. ($1 = 0.8535 euros) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approved sites in Spain, France, Germany, Italy, Poland and the US. At present, there are approximately 123 actively enrolling sites globally. According to the latest data collected by the European Cancer Information System (click here), a total of 12,861 new cases of breast cancer were diagnosed in Romania in 2022, which is the most common cancer diagnosed in women, representing approximately 28% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Romania with 3,877 deaths in 2022. The Company is collaborating with Dr. Nicoleta Antone, who is leading one of the largest academic breast cancer focused centers in Cluj Napoca, Romania, and her colleagues from at least 3 other sites in Romania. The Romanian clinical sites will be listed here with an interactive map. Dr. Antone will be serving as the national principal investigator in Romania for FLAMINGO-01. She is Head of Breast Cancer Centre at the Chiricuta Institute of Oncology in Cluj Napoca, Romania. She has been the Chair of the Romania Breast Cancer Group since 2021 and a member of the Women's Empowerment Cancer Advocacy Network since 2015. CEO Snehal Patel commented, "Romania is the first of several additional countries in Europe that we hope to add to Flamingo-01 as we now focus on mid-sized population countries with large population centers. We have visited the sites in Romania multiple times to assess study feasibility and provide training, and we are impressed with their facilities and commitment to the study. We look forward to working with Dr. Antone and her colleagues and have sufficiently advanced start-up activities this summer to be potentially screening and enrolling our first Romanian patients in the coming months." About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. For more information on FLAMINGO-01, please visit the Company's website here and here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@ About Breast Cancer and HER2/ Positivity One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at and follow the Company's Twitter at Forward-Looking Statement Disclaimer Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law. Company ContactSnehal PatelInvestor RelationsOffice: (832) 819-3232Email: info@ Investor & Public Relations Contact for Greenwich LifeSciencesDave GentryRedChip Companies 1-800-RED CHIP (733 2447)Email: dave@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
3 hours ago
- Newsweek
Two Key Trump Factors Divert European Travelers Away From US: TUI
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Tensions between the Trump administration and Europe and a stricter entry regime for the U.S. were given as the two primary factors causing a significant decline in travelers from the continent through TUI, Europe's largest tour operator. This drop is illustrative of how negative perceptions of the Trump administration's actions and rhetoric can feed back as tangible consequences for the U.S., in this instance a negative effect on the country's tourism industry. Sebastian Ebel, CEO of TUI Group, said in a media call on Wednesday, August 13, to coincide with the company's quarterly results, that its customers are now looking to Canada, Africa, and Asia instead of the U.S. "The main reasons for it being the tensions we see, but also news about travel into the U.S. becoming more difficult," Ebel said in a subsequent comment sent to Newsweek. He noted that U.S. travel is "relatively small for TUI, therefore this does not have a big impact on us," and that whenever there are tensions in one destination, its customers can easily choose another instead, as seen here. The Trump administration has clashed with the European Union (EU) over trade, and a number of European states have issued updated travel advisories due to tighter entry requirements at the U.S. border. President Donald Trump has accused the EU of fomenting an imbalanced and unfair trading relationship with the U.S. to its advantage and imposed tariffs. The U.S. and EU have since agreed on a new trade deal. His administration is also tightening the border to stem the flow of illegal immigration, which Trump said was out of control. This is a developing article. Updates to follow.
